Robo.ai Announces Proposed Establishment of Alif Maritec, a Marine Security and Intelligent Maritime Infrastructure Company
Wholly owned subsidiary of Alif Holding to focus on maritime protection, smart ports, underwater intelligence and critical infrastructure protection; Dr. Jasem Al-Mansory expected to serve as Chairman ABU DHABI, UAE, Sept. 9, 2026 /PRNewswire/ --...
Youlife Group, Inc. Announces Participation in the Skyline Signature Series Webinar
SHANGHAI, Sept. 9, 2026 /PRNewswire/ -- Youlife Group Inc. ("Youlife" or the "Company") (NASDAQ: YOUL), a leading blue-collar lifetime service provider in China, is pleased to announce that Stanley Yang, Chief Strategy Officer, will be delivering a...
Thoma Bravo Announces Strategic Growth Investment in Tanda
Investment to accelerate Tanda's product innovation and global growth BRISBANE, Australia and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Thoma Bravo, the world's largest software-focused investment firm, today announced a strategic growth...
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner...
Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy
SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and...
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state in non-human primate (NHP) studies utilizing Ascletis' proprietary Peptide Oral...
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet , one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's...
Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2026
SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Gamehaus Holdings Inc. ("Gamehaus" or the "Company") (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced its unaudited financial results for the fourth quarter and the full fiscal year...
Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend
BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited...